Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
Want to see HK:2196 full AI Analyst Report?
2196 Stock Chart & Stats
HK$19.63
-HK$0.04(-0.30%)
At close: 4:00 PM EST
HK$19.63
-HK$0.04(-0.30%)
Day’s Range― - ―
52-Week RangeHK$15.34 - HK$29.00
Previous CloseN/A
Volume1.35M
Average Volume (3M)8.63M
Market Cap
HK$62.41B
Enterprise ValueHK$88.21B
Total Cash (Recent Filing)HK$15.29B
Total Debt (Recent Filing)HK$31.86B
Price to Earnings (P/E)16.6
Beta1.13
Next Earnings
Sep 01, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)1.30
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.18Price Target Upside58.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.48
Revenue Forecast (FY)HK$43.79B
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundA sustained TTM revenue rebound of +158.4% signals resumed demand and commercial recovery across manufacturing, distribution and services. Durable top-line growth helps restore scale economics, supports reinvestment in product development and distribution coverage over the next 2–6 months.
Healthy Gross And Net MarginsHigh gross margin (~49%) with recovering net margin (~8.1%) indicates structural pricing power or favorable product mix in pharmaceuticals and distribution. These margins provide persistent cushion to absorb pricing pressure, fund R&D and sustain profitability through normal industry cycles.
Operating Cash Flow And FCF Turned PositiveReturn to positive operating cash flow and FCF after prior deficits demonstrates improving cash generation and working-capital management. This durable improvement increases ability to fund capex, service debt, and support strategic investments without heavy reliance on external financing.
Bears Say
Weak Cash ConversionFCF equating to ~24% of net income shows earnings do not reliably convert to cash. Persistently low cash conversion raises risk that earnings growth won’t translate to liquidity for capex, dividends or debt reduction, making the firm vulnerable to working-capital swings or higher investment needs.
Moderate Leverage And Average ReturnsA debt-to-equity near 0.75 creates meaningful fixed obligations while ROE around 7% is only modest. This combination limits financial flexibility and the company's ability to pursue large acquisitions or capex without increasing leverage, constraining strategic optionality over the medium term.
Margin Compression RiskDeclining EBITDA and only-moderate EBIT margins suggest cost pressure or adverse product mix. If sustained, margin erosion could reduce free cash generation and make it harder to fund R&D or expand services, requiring structural efficiency gains to restore durable profitability.
Shanghai Fosun Pharmaceutical (Group) Co News
2196 FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$15.34 and its highest was HK$29.00 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$62.41B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Sep 01, 2026 which is in 83 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.38 earnings per share for the quarter, beating the consensus estimate of HK$0.374 by HK$0.006.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.35 which represents an annual dividend yield of 1.69%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.43.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.38 in its last earnings report, beating expectations of HK$0.374. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2196
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
7.19%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
2196 Stock 12 Month Forecast
Average Price Target
HK$31.18
▲(58.81% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---